
McKesson (MCK) Stock Forecast & Price Target
McKesson (MCK) Analyst Ratings
Bulls say
McKesson is a well-established and diversified company, with a strong presence in the US and Canadian pharmaceutical markets. Their expansion into services and technology solutions allows them to diversify their revenue streams and adapt to the changing landscape of the healthcare industry. The company's strong partnerships, solid balance sheet, and expected revenue growth make it a promising investment option for those with a positive outlook on the healthcare sector.
Bears say
McKesson is facing various challenges in the pharmaceutical industry, such as declining coverage for certain drugs and potential biosimilar adoption, while also aiming to expand into higher-margin services and sustain growth through targeting gene therapy products and focusing on high-growth and complex categories. The company has a strong presence in the industry and has reached a settlement for ongoing litigation, but there are potential risks and limitations to their growth, such as changes in reimbursement and the distraction of a planned spin-off. Additionally, McKesson's distribution economics are dependent on contracts but have shown a history of generating operating leverage and improving efficiency.
This aggregate rating is based on analysts' research of McKesson and is not a guaranteed prediction by Public.com or investment advice.
McKesson (MCK) Analyst Forecast & Price Prediction
Start investing in McKesson (MCK)
Order type
Buy in
Order amount
Est. shares
0 shares